Company Overview

Strata Skin Sciences, Inc. is a U.S.-based medical technology company focused on developing, commercializing, and servicing in-office dermatologic systems. The company operates within the medical devices and dermatology healthcare industries, with a primary emphasis on chronic skin conditions that require ongoing treatment under physician supervision.

The company’s core business centers on proprietary energy‑based dermatology platforms used to treat conditions such as psoriasis, vitiligo, acne, and other inflammatory skin disorders. Its revenue model is differentiated by a recurring‑use structure in which dermatology practices pay per treatment rather than purchasing equipment outright, creating predictable utilization‑driven revenue. Strata Skin Sciences evolved through a series of restructurings and acquisitions that consolidated dermatology device technologies into a single platform‑focused business serving outpatient dermatology clinics.

Business Operations

Strata Skin Sciences generates revenue primarily through its recurring treatment fee model, device placements, and associated consumables. Its principal operating platforms include XTRAC®, VTRAC®, PHAROS®, and TheraClear®, each designed for specific dermatologic indications. These systems are placed in dermatology practices, and the company charges usage‑based fees tied to patient treatments, aligning its revenue with clinical utilization rather than capital sales cycles.

Operations are concentrated in the United States, where the majority of dermatology customers and installed systems are located, with limited international activity conducted through distributors. The company controls its core laser and light‑based technologies and provides ongoing clinical support, training, and service to physicians. There are no material joint ventures disclosed in public filings, but the company operates through wholly owned subsidiaries that hold intellectual property and commercial rights.

Strategic Position & Investments

Strata Skin Sciences’ strategy is centered on expanding utilization within its existing installed base while broadening indications for its platforms. Growth initiatives include increasing penetration among dermatology practices, expanding recurring treatment volumes per system, and pursuing regulatory clearances for additional dermatologic uses of its technologies.

Historically, the company has pursued targeted acquisitions to consolidate dermatology device assets, including the acquisition of Ra Medical Systems, which added excimer laser technology and expanded the company’s treatment portfolio. Strategic investment has focused on product enhancements, clinical validation, and reimbursement alignment rather than large‑scale diversification. The company remains concentrated on physician‑office dermatology rather than consumer or hospital markets.

Geographic Footprint

Strata Skin Sciences is headquartered in the United States and derives the vast majority of its revenue from U.S. dermatology practices. Its commercial footprint is primarily domestic, reflecting the structure of U.S. dermatology reimbursement and the company’s direct sales and service model.

Internationally, the company maintains a more limited presence through distributors in select markets across Europe, Asia, and other regions, though international revenue represents a relatively small portion of total operations. Strategic influence remains centered on the North American dermatology market, where treatment frequency and chronic disease prevalence support its recurring revenue approach.

Leadership & Governance

Strata Skin Sciences is led by an executive team with experience in medical devices, healthcare services, and commercial operations. Leadership emphasizes disciplined capital management, recurring revenue expansion, and close alignment with dermatology practices.

Key executives include:

• Dolev Rafaeli – Chief Executive Officer
• Paul Thomas – Chief Financial Officer
• Jeff Johnson – Chief Commercial Officer
• Robert Hagerty – Chief Operating Officer
• Steven Banoff – Chief Medical Officer

The board of directors oversees corporate governance with a focus on regulatory compliance, operational efficiency, and long‑term shareholder value creation.